Icelandic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
osteogenesis imperfecta/albumin
Krækjan er vistuð á klemmuspjaldið
5 niðurstöður
Variations in the serum concentration and urine excretion of alpha 2HS-glycoprotein, a bone-related protein, in normal individuals and in patients with osteogenesis imperfecta.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
The concentration of alpha 2HS-glycoprotein was measured in the serum and urine of normal individuals and of patients with osteogenesis imperfecta. The serum concentration of alpha 2HS-glycoprotein was higher in normal children than in adults. In women values showed a progressive age-related
Long-term Effects of Neridronate in Adults with Osteogenesis Imperfecta: An Observational Three-Year Italian Study.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
The aim of this study was to assess the long-term efficacy and safety of i.v. neridronate in the treatment of osteogenesis imperfecta (OI). One hundred and fourteen patients affected by OI were included in the study. Neridronate was administered by i.v. infusion at the dosage of 2 mg/kg, up to a
Do patients with osteogenesis imperfecta need individualized nutritional support?
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
OBJECTIVE
Information regarding nutrition and body composition in patients diagnosed with osteogenesis imperfecta (OI) is scarce. In the present study, nutritional status, bone mineral density, and biochemical parameters of subjects with OI were evaluated.
METHODS
Patients with type I OI (n = 13)
Treatment with neridronate in children and adolescents with osteogenesis imperfecta: Data from open-label, not controlled, three-year Italian study.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND
The present study assessed the long-term efficacy and safety of intravenous (i.v.) neridronate in children and adolescents affected by osteogenesis imperfecta (OI).
METHODS
55 young patients (mean age 12.6±3.9years) affected by OI were included in the study. Neridronate was administered
Noncollagenous proteins in normal and pathological human bone.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
The concentrations of alpha 2HS-glycoprotein, albumin, and sialic acid were measured in the bone of 28 normal individuals and 6 patients with osteogenesis imperfecta, 3 patients with Paget's disease, and 4 patients with either renal osteodystrophy, osteoporosis, osteomalacia, or osteopetrosis. The
Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum
- Virkar á 55 tungumálum
- Jurtalækningar studdir af vísindum
- Jurtaviðurkenning eftir ímynd
- Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
- Lestu vísindarit sem tengjast leit þinni
- Leitaðu að lækningajurtum eftir áhrifum þeirra
- Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum
Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum
